伏立康唑暴露与肺或造血细胞移植患者皮肤鳞状细胞癌风险:系统评价与Meta分析
该系统评价与Meta分析检索PubMed和Embase,纳入8项研究共3710例肺移植或造血细胞移植患者进行定性分析,其中5项进入Meta分析。结果显示伏立康唑使用与皮肤鳞状细胞癌风险显著增加相关(RR 1.86,95%CI 1.36-2.55),且风险不因移植类型或日照暴露校正而异;使用时间较长与风险正相关(RR 1.72,95%CI 1.09-2.72);伏立康唑使用与基底细胞癌风险增加无关(RR 0.84,95%CI 0.41-1.71)。
要点
- 伏立康唑使用与肺或造血细胞移植患者皮肤鳞状细胞癌风险显著增加相关(RR 1.86,95%CI 1.36-2.55)。
- 伏立康唑使用时间较长与皮肤鳞状细胞癌风险正相关(RR 1.72,95%CI 1.09-2.72)。
- 伏立康唑使用与基底细胞癌风险增加无关(RR 0.84,95%CI 0.41-1.71)。
核心结论
- 研究结果支持伏立康唑使用与肺移植或造血细胞移植患者皮肤鳞状细胞癌风险增加相关。
- 应进行常规皮肤科监测,尤其是在皮肤鳞状细胞癌高风险人群中。
研究设计与样本
- 系统评价与Meta分析,检索PubMed和Embase,采用随机效应模型计算合并相对风险(RR)及95%置信区间(CI)。
- 定性分析纳入8项研究共3710例肺移植或造血细胞移植患者,其中5项纳入Meta分析。
主要发现
- 伏立康唑使用与皮肤鳞状细胞癌风险显著增加相关(RR 1.86,95%CI 1.36-2.55)。
- 风险增加不因移植类型或日照暴露校正而异。
- 伏立康唑使用时间较长与皮肤鳞状细胞癌风险正相关(RR 1.72,95%CI 1.09-2.72)。
- 伏立康唑使用与基底细胞癌风险增加无关(RR 0.84,95%CI 0.41-1.71)。
临床怎么用
- 作者认为应进行常规皮肤科监测,尤其是在皮肤鳞状细胞癌高风险人群中。
局限性
- 回顾性观察性研究存在一些异质性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Current evidence about the association between voriconazole and risk of cutaneous squamous cell carcinoma (SCC) remains inconsistent. OBJECTIVE: To assess the association between voriconazole use and risk of SCC. METHODS: We systematically searched PubMed and Embase and performed a random effects model meta-analysis to calculate the pooled relative risk (RR) with a 95% confidence interval (CI). RESULTS: Of the 8 studies involving a total of 3710 individuals with a lung transplant or hematopoietic cell transplant that were included in the qualitative analysis, 5 were included in the meta-analysis. Use of voriconazole was significantly associated with increased risk of SCC (RR, 1.86; 95% CI, 1.36-2.55). The increased risk did not differ according to type of transplantation or adjustment for sun exposure. Longer duration of voriconazole use was found to be positively associated with risk of SCC (RR, 1.72; 95% CI, 1.09-2.72). Voriconazole use was not associated with increased risk of basal cell carcinoma (RR, 0.84; 95% CI, 0.41-1.71). LIMITATIONS: There were some heterogeneities in the retrospective observational studies. CONCLUSIONS: Our findings support an increased risk of SCC associated with voriconazole in individuals with a lung transplant or hematopoietic cell transplant. Routine dermatologic surveillance should be performed, especially among individuals at high risk of developing SCC.
引用
- Tang H, Shi W, Song Y, et al. Voriconazole exposure and risk of cutaneous squamous cell carcinoma among lung or hematopoietic cell transplant patients: A systematic review and meta-analysis. J Am Acad Dermatol. 2018. PMID: 30130598. doi:10.1016/j.jaad.2018.08.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。